Blood Based Biomarkers for Predicting Treatment Response to Immune Checkpoint Inhibitors After EGFR-TKI Resistance in Non-Small Cell Lung Cancer - PubMed
6 hours ago
- #immunotherapy
- #NSCLC
- #biomarkers
- Study explores blood-based biomarkers to predict response to immune checkpoint inhibitors (ICIs) in EGFR-mutant NSCLC after EGFR-TKI resistance.
- Retrospective analysis of 28 patients identified four plasma proteins (Gal-9, GZMH, IL-4, IL-6) differentiating durable clinical benefit (DCB) from non-responders.
- Lower Gal-9 and higher IL-4 levels correlated with longer progression-free survival (PFS) during ICI therapy.
- Plasma biomarkers could guide immunotherapy decisions post-EGFR-TKI resistance, avoiding the need for repeat biopsies.